Improving Clinical Trial Participation Through Patient-Centered Trial Design

Published May 12, 2014
Baltimore, MD, USA - Many people are reluctant to participate in clinical trials.  This reluctance stems from the perception of risk while not seeing any clear benefit to participation.  The exception is when an individual has a condition for which there is no effective treatment, and in this instance, the patient may have no other options. Researchers at the University of Maryland School of Pharmacy and PatientsLikeMe, a patient network where people can share and learn from real-world, outcome-based health data, believe that patients would be more willing to participate in research if trials were designed to be more patient-centered. Paul Wicks, PhD, Vice President of Innovation at PatientsLikeMe and a research neuropsychologist, fully understands the frustration patients face when clinical trials fail to live up to their expectations.  "Randomized controlled trials have traditionally been designed with the science in mind. But as patients become increasingly empowered through digital information, and engaged in managing their own condition, the traditional trial models need to evolve, too. We propose three potential upgrades that give patients a higher chance of maximizing their outcomes, avoiding harms, and integrating trials into everyday practice so that research becomes a part of care." C. Daniel Mullins, PhD, Professor at the University of Maryland School of Pharmacy, principal investigator of an AHRQ PCOR Research Infrastructure Development Grant, and lead author of the study, is familiar with the benefits the patient’s voice brings to the research process. “Many people think that comparative effectiveness research (CER) is only about observational studies, yet CER can and should include prospective trials as well.  In order for CER studies to be meaningful to patients, trials and other CER studies need to be patient-centered.” The full article, “Patient-Centeredness in the Design of Clinical Trials” is published in Value in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information:

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now